Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 51 Small Cell Lung Carcinoma 23 Breast Neoplasms 18 Sarcoma 17 Lung Neoplasms 10 Carcinoma, Hepatocellular 10 Esophageal Squamous Cell Carcinoma 9 Stomach Neoplasms 8 Neoplasms 8 Triple Negative Breast Neoplasms 7 Ovarian Neoplasms 7 Nasopharyngeal Carcinoma 7 Thyroid Neoplasms 6 Neoplasm Metastasis 6 Esophageal Neoplasms 6 Pancreatic Neoplasms 5 NSCLC 5 Colorectal Neoplasms 5 Carcinoma 5 Uterine Cervical Neoplasms 4 Pheochromocytoma 4 Endometrial Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Ovarian Epithelial 4 Recurrence 3 Paraganglioma 3 Non-squamous Non-small Cell Lung Cancer 3 Glioma 3 Fallopian Tube Neoplasms 3 Cholangiocarcinoma 3

Interventions

anlotinib 1 Chemotherapy, Adjuvant 1 Angiogenesis Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Stereotactic Body Radiation Therapy × anlotinib × Clear all

NCT04912128 2021-06-03

AnloSBRT

Peking University Third Hospital

Stereotactic Body Radiation Therapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡